EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Cost-effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma



Cost-effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma



Journal of Allergy & Clinical Immunology 109(1 Supplement): S185, January




(PDF emailed within 0-6 h: $19.90)

Accession: 034658307

Download citation: RISBibTeXText

DOI: 10.1016/s0091-6749(02)81685-2



Related references

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 20(13): 909-918, 2002

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 22(12): 815-825, 2004

Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. Treatments in Respiratory Medicine 4(2): 129-138, 2005

First-line therapy with fluticasone propionate/salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 109(1 Supplement): S252, January, 2002

Reduction in asthma-related exacerbations and exacerbation-related costs during initial maintenance therapy with fluticasone propionate/salmeterol combination product versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 111(2 Abstract Supplement): S143, February, 2003

Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate. Pharmacoeconomics 16 Suppl 2: I-Viii, 1-34, 2000

Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Annals of Allergy, Asthma & Immunology 95(2): 181-189, 2005

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma. Respiratory Research 8(): 67-67, 2007

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Annals of Allergy, Asthma & Immunology 88(2): 227-235, 2002

Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 5(): 179-187, 2010

A comparison of using fluticasone propionate/salmeterol combination versus adding montelukast in asthma patients experiencing symptoms on inhaled corticosteroids. Chest 118(4 Suppl ): 85S, October, 2000

Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50mug Diskus are stepped-down to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy & Clinical Immunology 113(2 Supplement): S94, February, 2004

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group. Respiratory Medicine 94(7): 724-732, 2000

Comparative efficacy of combination of fluticasone and salmeterol; fluticasone, salmeterol and montelukast; fluticasone, salmeterol, and levocetirizine in moderate persistent asthma: A study of 120 patients. Chest 132(4): 512a-1, 2007

Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Current Medical Research and Opinion 23(5): 1147-1159, 2007